Acer Therapeutics Management
William T. Andrews, M.D., FACP
Chief Medical Officer
Dr. Will Andrews joined Acer Therapeutics as Chief Medical Officer in October of 2017. He has worked in the biotech/pharmaceutical industry for 17 years in both Clinical Development and Medical Affairs, and has worked in multiple therapeutic areas, with a focus and extensive experience in rare diseases. Dr. Andrews has significant medical marketplace and product launch experience, having served as the medical lead for six product launches, including Xopenex HFA®, Brovana®, Alvesco®, Omnaris®, Catena®, and Juxtapid®. Most recently, he provided strategic consulting services to rare disease companies in Clinical Development, Medical Affairs, Go-To-Market/Launch planning, and Business Development/Corporate Strategy. Previously, Dr. Andrews held senior leadership positions and positions of increasing responsibility at Aegerion Pharmaceuticals, Santhera Pharmaceuticals, Sepracor, and ClinQuest. He received his undergraduate degree in Biology from Harvard University and his MD degree from Yale University School of Medicine. Dr. Andrews practiced medicine for 7 years full-time and 11 years part-time in the Boston area as a Board Certified Internist and an Attending Physician at Brigham and Women’s Hospital, and was on the Clinical Faculty at Harvard Medical School.
Stacey Bain, Ph.D.
VP, Clinical Operations
Dr. Bain joined Acer as Vice President, Clinical Operations in February 2018. She brings with her 20 years of international clinical operational and drug development experience in the pharmaceutical, biotechnology, and clinical research organization settings. Dr. Bain has managed or played an integral role in over 25 clinical trials, including both domestic and global studies. She oversaw two global Phase 3 oncology programs simultaneously with a combined budget of $75M. Dr. Bain’s experience includes management of various cross functional clinical development areas (clinical operations, drug safety, regulatory, data management, programming, biostatistics, medical writing, and third-party vendors). Previously, she held key leadership roles at Amunix Operating Inc., BioNumerik Inc., QLT Inc., InClin Inc., and PPD Development. Dr. Bain received a B.S. degree in Biomedical Science from Texas A&M University and a Ph.D. degree in Medical Science from Texas A&M College of Medicine.
Usman Iqbal MD, MPH, MBA
Vice President, Medical Affairs
Dr. Iqbal joined Acer as Vice President, Medical Affairs in July 2018. Dr. Iqbal is a medical executive with a portfolio career entailing 15 years of diverse experience spanning Medical Affairs and end-to-end evidence and value development, across both large and small cap biopharmaceuticals. His experience spans a number of therapeutic areas including in Neuroscience, as Senior Medical Affairs Leader at AstraZeneca, and in Oncology, as former Head of Sanofi Oncology, Global Evidence & Value Development (GEVD). With positions of increasing responsibilities across both R&D and Medical Affairs in different organizations, Dr. Iqbal has led five product launches, built several integrated and transversal medical affairs platforms, and led the development and execution of integrated medical affairs strategy for broad portfolios including several orphan drugs. His area of expertise also includes harnessing of big data science, advanced analytics and digital medicine to optimize medical affairs delivery and patient outcomes. Prior to working in the industry that also includes Amgen and Trevena, Dr. Iqbal was at the Boston University Health Outcomes Technology Group where he served as a senior research fellow at the Center for Assessment of Pharmaceutical Practices (CAPPs) and Veterans Affairs Pharmacy Benefit Management (VA-PBM). Dr. Iqbal serves as advisor to several academic and health care think tanks as an industry thought leader. He received his MD from Allama Iqbal Medical College, Lahore, Pakistan and MPH and MBA degrees from Boston University.
Chief Legal Officer
Don Joseph joined Acer as Chief Legal Officer and Secretary in April 2018. He has over 20 years of biopharmaceutical industry experience, including general counsel and senior management positions in biopharmaceutical and global health organizations. Mr. Joseph served as Chief Legal Officer and Board Secretary of KaloBios Pharmaceuticals, Inc., a publicly listed biopharmaceutical company. Prior to KaloBios, he was Chief Executive Officer, and before that, Chief Operating Officer of BIO Ventures for Global Health, or BVGH. Mr. Joseph is currently a member and Secretary of the BVGH board of directors, having served previously as its Chairman. He previously served as general counsel, corporate secretary, and in other senior management roles at publicly held biopharmaceutical companies, including Abgenix and Renovis. Mr. Joseph currently serves as lead independent director of Achieve Life Sciences, a publicly held pharmaceutical company. Before entering the life sciences industry, he practiced corporate law for a number of years in major firms, including as an international partner at Baker & McKenzie, one of the world’s largest law firms. Mr. Joseph received his J.D. degree from the University of Texas School of Law, with honors.
Terrie Kellmeyer, Ph.D.
Vice President, Clinical Science
Dr. Kellmeyer joined Acer as VP, Clinical Science in December 2017. She brings to Acer over 17 years of experience in the pharmaceutical industry spanning the areas of Clinical Development, Regulatory Affairs, Medical Writing and Medical Affairs. Over her career, Dr. Kellmeyer filed 3 NDAs, worked on a Brand Team preparing for product launch, and led clinical development programs. Prior to joining Acer, she served as Executive Director of Medical Writing and Scientific Communications at Intercept Pharmaceuticals where she was instrumental in leading scientific content and optimizing timelines for an NDA submission, served as a key member of the team for a positive Advisory Committee meeting, and oversaw all externally and internally facing scientific communications. Previously, Dr. Kellmeyer held positions of increasing responsibility in Clinical Development and Regulatory Affairs at Amylin Pharmaceuticals and Gen-Probe, Inc. She received a B.S. degree in Biotechnology from Rochester Institute of Technology and a Ph.D. degree in Cellular and Molecular Biology from SUNY Health Science Center at Syracuse.
Vice President, Manufacturing
Mr. Klopp joined Acer as Vice President, Manufacturing in January 2018. He brings 15 years of experience in the biopharmaceutical industry developing small molecule drug candidates in positions ranging from research to process development to contract manufacturing management. Mr. Klopp has spent the last 11 years working on the development and commercialization of orphan drugs at BioMarin Pharmaceutical (BMRN) and later Ultragenyx Pharmaceutical (RARE). His expertise includes selecting and managing contract manufacturing sites producing drug substance and various oral dosage forms including associated sponsor clinical and commercial CMC regulatory strategy. Mr. Klopp received a B.S. degree in Chemistry from Pennsylvania State University and a M.S. degree in Chemistry from University of California at Berkeley.
Jason Kneeland, CPA
Vice President, Finance, Controller
Mr. Kneeland joined Acer as VP Finance, Controller in November 2017. He brings nearly twenty years of progressive experience in the corporate finance leadership of technology and related companies. Prior to joining Acer, Mr. Kneeland was VP Finance at TechTarget, Inc., a public company with 700 employees and $100M of annual revenue, where he led a team responsible for the day-to-day finance and accounting operations, as well as several key initiatives around revenue recognition and systems implementations. Prior to TechTarget, Mr. Kneeland was a Senior Manager at CFGI, where he assisted domestic and international bio-tech and technology clients with public offerings, mergers and acquisitions and other complex accounting, reporting and internal-control matters. Prior to that, Mr. Kneeland was Director of Technical Accounting of a multi-billion-dollar publicly traded retail pharmacy and pharmacy benefit management company. He has fulfilled various accounting and reporting roles with publicly traded companies in the technology industry since beginning his career in the audit practice of KPMG LLP. Mr. Kneeland is a Certified Public Accountant in the state of Massachusetts and holds a Bachelor of Science in Accounting from Johnson & Wales University.
Vice President, Quality
Ms. Lonnroth joined Acer as Vice President, Quality starting in May 2018. She brings more than 20 years of experience implementing, improving and directing Quality initiatives in highly regulated global life science corporations. Ms. Lonnroth is a subject matter expert in Quality Assurance (QA) / Quality Control (QC) and Quality Management Systems (QMS) and has successfully hosted several FDA and other agency inspections and customer/partner audits. Prior to Acer, she has held leadership positions in Commercial and Pre-Commercial Quality at several companies including AMAG Pharmaceuticals, Celestica, Acusphere, Histogenics, Stryker Biotech and Alkermes. Ms. Lonnroth obtained her US Regulatory Affairs Certification (RAC[US]) from RAPS in 2011. She received her B.A. degree in Modern Languages and B.S./M.S. degrees in Chemistry at University of Massachusetts, Lowell and her MBA at Franklin Pierce University.
Vice President, Program and Alliance Management
Mrs. Mulready joined Acer as Vice President, Program and Alliance Management in April 2018. She has over 20 years of biotechnology experience with expertise in executional strategy and team leadership. Prior to joining Acer, she was Senior Director of Program and Alliance Management at Mersana Therapeutics where she launched the function with responsibility for establishing and leading governance and teams, driving the business processes to advance the multiple internal and partnered programs, and ensuring efficiency in delivering on goals across the portfolio. Previously, she held roles of increasing responsibility at ImmunoGen, Inc. spanning Program Management, Alliance Management and Discovery Research. Mrs. Mulready earned her B.A. degree in Biology from Colby-Sawyer College and her M.S. degree in Management from Lasell College.
Chief Financial Officer
Harry Palmin has more than 20 years of corporate experience. He spent 15 years at Novelos Therapeutics (NVLT), where he served as President and CEO and Board Director, and built the company from concept to a $500M peak market cap; raised $98 million in funding; and oversaw ten clinical studies in oncology (including pivotal Phase 3 studies) and infectious diseases. Previously, he held roles at Lehman Brothers and Morgan Stanley.
CEO & Founder
Chris Schelling has 18 years of biotech and pharma strategic and orphan drug expertise. Prior to founding Acer, he was Executive Director of Strategic Marketing at BioMarin Pharmaceutical (BMRN), where he was instrumental in the development and commercialization of the company’s phenylketonuria (PKU) franchise. Previously, he held roles at Abgenix, Cell Therapeutics, Stanford Research Institute Consulting, and Organon.
Vice President, Market Access and Reimbursement
Mr. Seibt joined Acer as Vice President, Market Access and Reimbursement in April 2018. He has over 22 years of health care industry experience, with 15 years of specialization in managed care market access and reimbursement. During his career, Mr. Seibt has successfully launched 18 products in primary care, specialty, and rare diseases. Prior to joining Acer, he was the Director of Account Management, where he led a field market access team dedicated to securing distribution, formulary coverage, and reimbursement of Biogen’s portfolio in hemophilia, multiple sclerosis, and spinal muscular atrophy. Previously, Mr. Seibt has held roles in sales, marketing, and market access at Pfizer, Vertex, PCA HealthPlans and PacifiCare. He received his degree in economics at The University of Texas and completed the healthcare leadership program at Portland State University.